Streetbeat News

Revenues

VZ

Verizon Communications (NYSE:VZ) has been the subject of diverse analyst opinions over the past quarter, with 13 experts offering a range of views. Recent ratings show a shift towards a more neutral stance in the last 30 days compared to previous months. The 12-month price targets for VZ have seen an increase, with an average target of $44.38, marking a 7.25% rise from the previous average of $41.38. Analyst actions include various adjustments to ratings and price targets, reflecting changing market dynamics and company performance. Verizon's financials indicate challenges in revenue growth and net margin, but a strong market presence and sound financial structure are noted.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 4:01 pm

BBY

Best Buy Co (NYSE:BBY) received mixed analyst ratings over the past three months, with a total of 13 analysts providing insights. The ratings ranged from bullish to bearish, with the majority being indifferent. The average 12-month price target for Best Buy has increased by 11.1% to $85.08, with adjustments in ratings and price targets by analysts from firms like JP Morgan, Telsey Advisory Group, and Morgan Stanley. Best Buy, a leading consumer electronics retailer, reported a slight revenue decline of -0.6% but showcased strong profitability and financial health with a net margin of 3.14% and ROE of 15.69%.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 4:00 pm

NKE

Nike Inc (NYSE:NKE) reported Q3 results that exceeded expectations but announced a low single-digit revenue decline for the first half of fiscal 2025, leading to a bearish outlook. The stock has been underperforming, down 26% over the past year and 14.3% year-to-date. Technical indicators such as MACD, RSI, and Bollinger Bands signal a strong downward trend and selling pressure. Despite surpassing Q3 expectations, the revised revenue projections have negatively impacted investor sentiment.

Portfolio Pulse from Surbhi Jain

March 22, 2024 | 3:48 pm

CHPT

ChargePoint Holdings Inc (NYSE:CHPT) shares dropped 7.9% to $1.74, retracting after gains earlier in the week due to the Federal Reserve's decision to maintain interest rates at 5.25% to 5.5%. The Fed plans three rate cuts in 2024, targeting a 4.6% rate, despite internal dissent. Lower future rates and revised economic growth projections for 2024 could benefit ChargePoint by boosting economic activity and electric vehicle adoption. ChargePoint does not pay dividends but may engage in other capital allocation strategies.

Portfolio Pulse from Henry Khederian

March 22, 2024 | 3:35 pm

BIOL

VXF

BIOLASE, Inc. (NASDAQ:BIOL) shares surged after reporting a smaller-than-expected Q4 FY23 EPS loss. Despite revenue slightly missing estimates, the company's outlook for FY24 is positive, with expected net revenue growth and positive adjusted EBITDA. BIOLASE's growth is attributed to increased adoption of its dental lasers and consumables. Investors can also gain exposure to BIOLASE through the Vanguard Extended Market ETF (NYSE:VXF).

Portfolio Pulse from Lekha Gupta

March 22, 2024 | 3:13 pm

APPN

Over the last three months, Appian (NASDAQ:APPN) has been reviewed by 5 analysts with mixed opinions ranging from bullish to bearish. Recent assessments show a shift towards a more cautious stance, with the average 12-month price target for APPN now at $46.8, down from $47.60. Analyst actions include both upgrades and downgrades, reflecting changing market dynamics and company performance. Appian, a low-code enterprise platform-as-a-service company, has shown a revenue growth rate of 15.53% as of December 31, 2023, but struggles with profitability and efficient asset utilization.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 3:01 pm

PEGA

Analysts have provided diverse opinions on Pegasystems (NASDAQ:PEGA) with a mix of bullish to bearish ratings over the past quarter. The recent evaluations show an average 12-month price target of $67.33, marking a slight increase from the previous $67.00. Key analysts from firms like Citigroup, DA Davidson, RBC Capital, Goldman Sachs, Wedbush, and Barclays have updated their ratings and price targets, reflecting changes in market dynamics and company performance. Pegasystems, known for its Pega Infinity platform, has shown notable revenue growth and strong financial metrics such as net margin and ROE, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 3:00 pm

OVV

Analysts have provided mixed reviews on Ovintiv (NYSE:OVV) over the past three months, with recent ratings ranging from bullish to indifferent. The average 12-month price target for OVV has increased to $54.75, up 7.88% from the previous target. Analyst actions include both raises and lowers in ratings and price targets, reflecting dynamic market conditions and company performance. Ovintiv's financial performance shows challenges in revenue growth and profitability, with a notable decline in revenue and below-average net margin and ROE, but an impressive ROA and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 3:00 pm

DK

Four analysts have recently updated their ratings on Delek US Holdings (NYSE:DK), with a mix of 'Neutral' and 'Underweight' ratings. The average 12-month price target has been raised to $29.00 from $26.50, indicating a positive sentiment shift. Despite this, Delek faces challenges such as revenue decline, below-average ROE and ROA, and high debt-to-equity ratio, suggesting mixed financial health.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 3:00 pm

NARI

Inari Medical (NASDAQ:NARI) has been the subject of varied analyst opinions over the past three months, with 7 analysts offering insights ranging from bullish to bearish. The average 12-month price target for NARI has been adjusted to $65.57, down from $72.00, indicating a 8.93% decrease. Analyst actions include maintaining, raising, and lowering ratings and price targets, reflecting their reaction to Inari Medical's performance and market conditions. Inari Medical, a medical device company, has shown notable revenue growth and strong financial health indicators such as net margin, ROE, and ROA, despite a market capitalization below industry averages.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 2:01 pm